Clinical trial
A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine
NCT00334178 is registered in ClinicalTrials.gov with Lotus Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine
- Lead sponsor
- Lotus Pharmaceutical
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2004
- Completion date
- September 30, 2006
- Enrollment
- 74 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.